Showing 9711-9720 of 20328 results for "".
- Early-Life Added Sugars (≤2 years): Intake Patterns, Contributors, and Key Associationshttps://reachmd.com/news/early-life-added-sugars-2-years-intake-patterns-contributors-and-key-associations/2485934/Investigators in the Nutrients report from the MAS‑Lactancia cohort examined added sugar (AS) intake across complementary-feeding ages and described how
- Remote Ischemic Conditioning Reported to Protect Heart During Anthracycline Therapyhttps://reachmd.com/news/remote-ischemic-conditioning-reported-to-protect-heart-during-anthracycline-therapy/2485901/A report describes preclinical work in tumor-bearing mice receiving anthracycline chemotherapy in which remote ischemic conditioning (RIC)—brief, controlled interruptions of
- MDA Research Momentum Award: Łukasz Sznajder Named Inaugural Recipienthttps://reachmd.com/news/mda-research-momentum-award-ukasz-sznajder-named-inaugural-recipient/2485905/In a press release, the Muscular Dystrophy Association (MDA) announced that Łukasz Sznajder, PhD, MSc, an assistant professor in the Department of Chemistry and Biochemistry at the University of Nevada, Las Vegas, has been named the first recipient of its new
- Global Breast Cancer Burden Rising Fastest in Low-Income Countrieshttps://reachmd.com/news/global-breast-cancer-burden-rising-fastest-in-low-income-countries/2485900/Annual new female breast cancer cases worldwide are projected to rise from an estimated 2.3 million in 2023 to more than 3.5 million by 2050, with annual deaths projected to increase from around 764,000 to 1.4 million over the same period, according to the news summary. The summary attribut
- ICU Stewardship Linked to Lower Broad‑Spectrum Use, Improved Gram‑negative Susceptibility, and Cost Savingshttps://reachmd.com/news/icu-stewardship-linked-to-lower-broadspectrum-use-improved-gramnegative-susceptibility-and-cost-savings/2485903/Investigators in Brazil reported an interrupted time-series evaluation of an Antimicrobial Stewardship Program (ASP) introduced in January 2021 in the adult ICU of a high-complexity public hospit
- Internal Mammary Vessels Lead in Autologous Breast Reconstruction, Review Findshttps://reachmd.com/news/internal-mammary-vessels-lead-in-autologous-breast-reconstruction-review-finds/2485836/Autologous breast reconstruction most commonly relies on free tissue transfer to achieve natural-appearing and aesthetically favorable outcomes. In a narrative review published in Gland Surgery, the authors examined recipient vessel selection strategies and their clinical implications in
- Dapiglutide Phase IIa: Safety, Modest Metabolic Signals but No Significant Weight Benefit at 12 Weekshttps://reachmd.com/news/dapiglutide-phase-iia-safety-modest-metabolic-signals-but-no-significant-weight-benefit-at-12-weeks/2485891/A randomized, double-blind phase IIa trial in adults with obesity evaluated weekly dapiglutide, described as a dual GLP-1/GLP-2 receptor agonist, versu
- Paramagnetic Rim Lesions Predict Conversion to Clinical MS in Radiologically Isolated Syndromehttps://reachmd.com/news/paramagnetic-rim-lesions-predict-conversion-to-clinical-ms-in-radiologically-isolated-syndrome/2485881/In a prospective multicenter cohort study published in JAMA Neurology, paramagnetic rim lesions (PRLs) detected on susceptibility-sensitive MRI in individuals with radiologically isolated syndrome (RIS) were associated with increased risk of developing clinical multiple sclerosis (MS). A
- Nirsevimab Real‑world Effectiveness and Early Pathogen Shifts in Italian Infant LRTI Hospitalizationshttps://reachmd.com/news/nirsevimab-realworld-effectiveness-and-early-pathogen-shifts-in-italian-infant-lrti-hospitalizations/2485883/A nationwide, retrospective multicenter analysis across 19 Italian pediatric centers describes infants hospitalized for lower respiratory tract infection (LRTI) during the first RSV season after nirs
- Phase III SIMBA: MB09 vs Prolia — Key Efficacy, PK/PD, Safety Findingshttps://reachmd.com/news/phase-iii-simba-mb09-vs-prolia-key-efficacy-pkpd-safety-findings/2485867/The published SIMBA phase III article reports a randomized, double-blind comparison of MB09 (a denosumab biosimilar) versus reference denosumab (Prolia)